ISN-ACT Clinical Trial List: January 2019
ISN Academy. ISN-ACT . 01/16/19; 256980; 4800 Topic: General Nephrology
Disclosure(s): The ISN-Advancing Clinical Trials is a new initiative of the ISN intended to leverage existing infrastructures within ISN, in order to improve global nephrology community participation in clinical trial research. As part of its activities, the ISN-ACT highlights and sometimes analyzes important recent nephrology trials from latest medical literature every month through the ISN-ACT Trial-list. Editors of the ISN-ACT Trial-List also select clinical trials of particular impact, and collaborate with the @ISNeducation social media learning team to represent these trials visually. Join the ISN-ACT To generate more high-quality clinical trials and studies in nephrology, ISN-ACT is calling on investigators and interested individuals. If you are an ISN member interested to join this great initiative, submit your application online. Use the button below (download PDF) to download this month's edition of the list.
Login now to access Regular content available to all registered users.

You may also access ISN content "anytime, anywhere" with the FREE ISN Academy App for iOS and Android.
Discussion Forum (0)
Rate & Comment (0)
Once a month, the ISN-ACT (Advancing Clinical Trials) team collects and publishes a list of important nephrology trials from the latest medical literature. Each trial is reviewed in context and their risk of bias in seven key areas assessed. This month, we reviewed the following trials:

- C1 esterase inhibitor reduces the burden of delayed graft function in early phase trial
A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients Jordan, et al. Am J Transplant. 2018;18(12):2955-2964

- Spironolactone passes first hurdle on the way to larger studies in dialysis recipients
Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial
Charytan, et al. Kidney Int. 2018 Nov 22. pii: S0085-2538(18)30641-0

- ARB better tolerated than ACE inhibitor or combination
The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial
Saglimbene, et al. J Am Soc Nephrol. 2018 Nov 12. pii: ASN.2018040443

- Low-dose steroids plus mycophenolate vs. standard-dose steroids: no change for minimal change
An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study)
Rémy, et al. Kidney Int. 2018;94(6):1217–1226

- No benefit from vitamin D analogue in hemodialysis patients with normal mineral parameters
Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial
Shoji et al. JAMA. 2018;320(22):2325-2334

- Recombinant alkaline phosphatase does not improve sepsis-induced AKI
Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial
Pickkers et al. JAMA. 2018;320(19):1998-2009

- No role for somatostatin analogue lanreotide in ADPKD
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease – The DIPAK 1 Randomized Clinical Trial
Meijer et al. JAMA. 2018;320(19):2010-2019

A preview of this infographic is available below, and can be downloaded to the left.

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies